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Introduction
Rain and the city of Glasgow are almost synonymous and
sadly this was indeed the case for the duration of the
British Cancer Research Meeting 2002, held at the Scot-
tish Exhibition and Conference Centre from 30th June to
3rd July. The rain did not dampen the spirits of the almost
600 delegates, however, and a feast of good science was
enjoyed. This ranged from plenary sessions and award
lectures to proffered paper sessions and posters, covering
various aspects of clinically diagnosed and experimental
cancer models. Here we present some of the highlights.
Meeting report
A number of scientists, both young and established, were
honoured at the meeting for their contributions to cancer
research. The British Association for Cancer Research
(BACR) Tom Connors Award Lecture “Close Encounters of
a Molecular Kind” was given by Malcolm Stevens (University
of Nottingham, UK). In his lecture, he outlined the need to
nurture ‘cunning’ rather than ‘stunning’ chemistry as the way
forward in drug discovery. The BACR Translational
Research Award went to his colleague Tracey Bradshaw for
her work on Phortress. In an eloquent presentation, the
history of Phortress was outlined, underlining the interplay
between chemistry and biology that led to its development
and selection as a candidate therapy. Phortress evolved
from polyhydroxylated 2-phenylbenzothiazoles designed as
potential tyrosine kinase inhibitors. In laboratory studies it
has shown very promising results in treating breast and
ovarian cancers and it will shortly be undergoing Phase I
clinical trials. Marie Boyd (University of Glasgow, UK)
received the BACR Young Scientist Award and outlined the
exciting prospect of linking conventional radiation-based
therapies with gene therapy for treating malignancy.
In “Re-designing Cancer Therapy”, Sir David Lane (Univer-
sity of Dundee, UK) emphasised the need for patient-spe-
cific therapy, a consensus that was reiterated throughout
the conference. He also discussed the necessity of
looking not only at the gene in question, but also at the
whole signalling pathway in which it is involved. We were
reminded that 24% of human breast cancers have genetic
changes in the p53 tumour suppressor gene and how p53
may be utilised as a target for gene therapy. The role of
p53 as a potential therapeutic target was also empha-
sised by Barbara Foster (Pfizer Global R&D, Groton, CT,
USA). Current strategies include the pharmacological
rescue of mutant p53 protein, using small chaperone
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The 2002 British Cancer Research Meeting was held from 30th June to 3rd July in Glasgow, UK. The
meeting was structured to include educational workshops, plenary lectures, symposia, and poster
sessions, which brought together scientists and clinicians. Presentations ranged from the impact that
modifications to basic chromatin structure can have on diagnosis and targeted gene therapy, to the
outcome of novel therapeutics through clinical trials. The emphasis was clear: patient survival is the
main priority and treatment of organ-specific cancer must inevitably be replaced by individualised
tumour-specific therapy.
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molecules. Both speakers discussed various therapeutic
strategies for tumours that have mutations in the p53 gene
and left us with the notion that the future of p53 as a ther-
apeutic target was very much alive.
The Cancer Research UK Lecture was given by Olli
Kallioniemi (National Genome Research Institute,
Bethesda, MD, USA), who discussed the application of
array technology in cancer research. From the construc-
tion of simple RNA or DNA arrays, this field has evolved
rapidly in recent years. The emerging challenge now is to
uncover the function of the many candidate genes identi-
fied in earlier genome arrays by integrating gene copy
number and gene expression analysis with functional
studies. The development of tissue microarrays, in which it
is theoretically possible to represent an entire pathology
archive on a single microscope slide (‘pathomics’), is one
way forward for such high-throughput analysis. Tissue
microarrays allow population-level screening and cellular
resolution, which are not possible using genome arrays. A
novel slant is the use of living gene transfection microar-
rays [1]. With this technique, cultured cells are overlaid on
DNA arrays. Those cells that take up DNA create spots of
localised transfection. This exciting new technology has
applicability for identifying new drug targets and in discov-
ering gene products which affect cell physiology.
Another innovative angle involves harnessing the power of
gene transfection microarrays with RNA interference [2].
RNA interference involves the processing of dsRNA to
short interfering RNA of about 21 nucleotides, as a form of
post-transcriptional gene silencing. This is often mani-
fested in an aberrant phenotype, which can allow gene
function to be identified. Quite literally we now have avail-
able an array of arrays and, bearing in mind how rapidly
this field continues to evolve, the ‘laboratory-on-a-chip’
may soon be here.
The importance of histone modification and chromatin
remodelling is becoming increasingly recognised, particu-
larly since many important genes are methylated and epige-
netically silenced in tumours. In a whole session dedicated
to this subject, the audience was educated on a range of
topics, from basic principles of chromatin structure, to the
role of histone modifying proteins and methylation in chro-
matin remodelling. Histone deacetylases and DNA methyl-
transferase inhibitors could represent new diagnostic or
therapeutic targets. Tony Kouzarides (Wellcome/Cancer
Research UK Institute, Cambridge, UK) initiated this
session in the BACR Frank Rose Lecture, giving an invigo-
rating and informative insight into the role of “Histone Modi-
fications in Transcriptional Control”. Particular emphasis
was given to the effect of gene methylation on transcrip-
tional repression, and he gave an illustrative demonstration
of the downstream effects of these events. Interestingly, he
used the estrogen receptor (ER)-regulated gene pS2 as a
model to demonstrate the complex sequence of events
regulating gene transcription. The focus of the talk was on
lysine and arginine methylation. Using chromatin immuno-
precipitations, he showed that methylation of arginine 17
on the histone (H3) tail is required for activation of the pS2
gene. The order of events involves recruitment of histone-
modifying proteins, acetylation, and subsequent methyla-
tion of the gene before its activation. The presentation was
concluded with the possibility of using this detailed infor-
mation on pS2 to produce better defined targets for
therapy and molecular diagnosis.
Individual tumours have different patterns of methylation,
and Robert Brown (University of Glasgow, UK) also
emphasised the potential of identifying gene methylation
patterns in specific tumours. Nick La Thangue (University
of Glasgow, UK) highlighted the use of histone deacety-
lase inhibitors as cancer therapeutics. One candidate,
PXD101, is a novel histone-deacetylase antagonist that
blocks tumour growth by inducing apoptosis and has little
toxicity in mice. Advances in cancer therapeutics are con-
tinually ongoing, and novel strategies using DNA methyl-
transferase inhibitors and histone-deacetylase inhibitors
are already showing promise in clinical trials.
New predictive markers for breast cancer are always being
sought and work presented by Ramsey Cutress (University
of Southampton, UK) showed that BAG-1, a multifunctional
protein with targets including heat shock proteins and
some nuclear hormone receptors, may have potential in
predicting response to hormonal therapy. In a study of 138
breast cancers, nuclear expression of BAG-1 was associ-
ated with improved survival. BAG-1 interacts directly with
ER-α and -β. Brid Ryan (St Vincent’s University Hospital,
Dublin, Eire) showed that survivin, an inhibitor-of-apoptosis
protein, may have potential in prognosis. Survivin is overex-
pressed in many tumours, including breast, is inversely cor-
related with expression of ER and progesterone receptor
and is positively correlated with tumour grade.
Current indicators of response to breast cancer therapy
rely on the hormonal status of tumour tissue. Tumours
responsive to endocrine hormones are treated with the ER
antagonist tamoxifen. The therapeutic efficacy of tamoxifen
is compromised by its agonistic activity in some tissue
types. Mitch Dowsett (Royal Marsden NHS Trust, London,
UK) highlighted that ER-negative (ER–)/progesterone
receptor-positive patients also benefit from hormonal
therapy and suggested that identification of progesterone
receptor in the small subset of ER– tumours (25%) should
also be ascertained prior to selecting adjuvant therapy. He
described the reduced benefit tamoxifen might have on
patients that have ER+ and HER-2+ tumours.
Matti Aapro (Clinique de Genolier, Switzerland) addressed
a number of consensus guidelines for adjuvant therapy,204
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and both Aapro and Dowsett summarised the findings of
the recent ATAC trial in which the aromatase inhibitor
anastrozole was found to be superior to tamoxifen or a
combination of both drugs in treating postmenopausal
women with early breast cancer [3]. Aapro proposed the
use of adjuvant drugs such as Paclitaxel, in the early treat-
ment of breast cancer, to improve patient survival. He con-
cluded that one specific drug treatment will not prove
successful for all patients and that organ-specific cancer
treatment will soon be superseded by tumour-specific
therapy. This idea was reinforced by Dowsett, who encour-
aged the idea that tumours should be seen as individual
entities and should be treated specifically.
Tumour metastases and drug resistance remains a burden
on the current treatment of breast cancer. Both Graham
Roche-Nagle (Beaumont Hospital, Dublin, Eire) and
Thomas Barry (Mater Hospital, Dublin, Eire) presented
data illustrating the role that cyclo-oxygenase-2 (COX-2)
may play in these events. Using selective COX-2 inhibition
Roche-Nagle demonstrated a significant reduction in the
number of tumour metastases in an orthotopic murine
model of breast cancer. Microvessel density and levels of
serum vascular endothelial-cell growth factor were also
reduced by COX-2 inhibition.
Drug delivery and targeting are important aspects of
cancer therapy that were covered in several presentations.
The story of 5-(aziridin-l-yl)-2,4-dinitrobenzamide (CB1954)
was presented by Richard Knox (Enact Pharma plc, Salis-
bury, UK). CB1954, developed in the 1950s, is a proven
success in eradicating rat tumours, but unfortunately the
same effect was never observed in human cancers. This is
due to differences in the bioactivation of CB1954 in rats
versus humans: the human form of the enzyme DT-
diaphorase (NQ01) is much less efficient at metabolising
CB1954, which accounts for its lack of activity against
human cancers. New research has identified an enzyme
(NQ02) in some human tumours, although not those of the
breast. NQ02 is several-fold more effective than NQ01 at
metabolising CB1954 and a Phase I trial is about to
begin, with the aim of establishing the efficacy of NQ02 as
a more active substrate for CB1954.
Ruth Duncan (University of Cardiff, UK) presented an
overview of tumour-specific drug delivery using
polymer–anticancer conjugates. To date, successful
receptor-mediated targeting has been limited to the asialo-
glycoprotein receptor in hepatic carcinomas, but
HER2/neu, present in some breast cancers, could repre-
sent a new target for polymer-based drug delivery.
Gerry Potter (De Montfort University, Leicester, UK)
described some of the actions of the human cytochrome
P450 CYP1B1, the overexpression of which has been
observed in many tumours, including breast. Many
cytochrome P450 enzymes are known to metabolise a
variety of anticancer drugs; the consequence of
cytochrome P450 metabolism is usually detoxification of the
drug, although bioactivation occurs in some cases. With
this in mind he proposed that CYP1B1 be reclassified as a
tumour-suppressor enzyme, through natural prodrug bioac-
tivation. He presented data showing that some natural
dietary agents, such as phytoestrogens and resveratrol, are
converted into anticancer agents by CYP1B1.
Conclusion
As with most international conferences, the gathering of
many researchers, scientists and clinicians results in the
generation of novel ideas and extensive discussions. The
outcome, foremost, drives delegates forward in their areas
of cancer research. As the ultimate focus is on improving
patient survival using chemopreventative and chemothera-
peutic drugs, we are reminded of the demands of the
patient. Perhaps the most significant message from this
meeting is the necessity and inevitable development of a
tumour-specific drug that is tailored to each patient’s gene
profile, thus meeting their individual requirements. This is
keenly awaited. Perhaps the results of research in these
areas, including interim results from the Phase I trials men-
tioned above, will be presented at the next meeting. The
next British Cancer Research Meeting will take place at
the Bournemouth International Conference Centre on 2–5
July 2003 (http://www.icr.ac.uk/bacr/home.htm).
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